What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines

(2017) Filip Ventorp et al.   Journal of Parkinsons Disease

Multi-dimensional analysis on Parkinson’s disease questionnaire-39 in Parkinson’s patients treated with Bushen Huoxue Granule: A multicenter, randomized, double-blinded and placebo controlled trial

(2016) Min Li et al.   COMPLEMENTARY THERAPIES IN MEDICINE

GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality

(2016) Rozita H Anderberg et al.   PSYCHONEUROENDOCRINOLOGY

Diagnostic Validity and Factor Analysis of Montgomery-Asberg Depression Rating Scale in Parkinson Disease Population

(2015) Tharini Ketharanathan et al.   JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY

Quantitative assessment of non-motor fluctuations in Parkinson’s disease using the Non-Motor Symptoms Scale (NMSS)

(2015) Alexander Storch et al.   JOURNAL OF NEURAL TRANSMISSION

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment

(2015) Javier Pagonabarraga et al.   LANCET NEUROLOGY

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

(2015) Iciar Aviles-Olmos et al.   Journal of Parkinsons Disease

Sex Differences in Clinical Features of Early, Treated Parkinson’s Disease

(2015) Erika F. Augustine et al.   PLoS One

Premotor and nonmotor features of Parkinsonʼs disease

(2014) Jennifer G. Goldman et al.   CURRENT OPINION IN NEUROLOGY

EuroInf: AMulticenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease

(2014) Pablo Martinez-Martin et al.   MOVEMENT DISORDERS

The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment

(2014) Eva Pirogovsky et al.   PARKINSONISM & RELATED DISORDERS

Depression and Parkinson’s Disease: Current Knowledge

(2013) Laura Marsh   Current Neurology and Neuroscience Reports

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale

(2013) P. Martinez-Martin et al.   EUROPEAN JOURNAL OF NEUROLOGY

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

(2012) David G Parkes et al.   Expert Opinion on Drug Discovery

Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease

(2011) David A. Gallagher et al.   MOVEMENT DISORDERS

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)

(2010) Claudia Trenkwalder et al.   MOVEMENT DISORDERS

International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease

(2009) P. Martinez-Martin et al.   NEUROLOGY